Literature DB >> 2893226

Resumption of HIV antigen production during continuous zidovudine treatment.

P Reiss, J M Lange, C A Boucher, S A Danner, J Goudsmit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2893226     DOI： 10.1016/s0140-6736(88)91219-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Antigen detection for human immunodeficiency virus.

Authors:  D J Harry; M B Jennings; J Yee; J R Carlson
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

2.  Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.

Authors:  N S Zeidner; M H Myles; C K Mathiason-DuBard; M J Dreitz; J I Mullins; E A Hoover
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.

Authors:  M Baba; E De Clercq; H Tanaka; M Ubasawa; H Takashima; K Sekiya; I Nitta; K Umezu; H Nakashima; S Mori
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Drug Resistance Evolution in HIV in the Late 1990s: Hard Sweeps, Soft Sweeps, Clonal Interference and the Accumulation of Drug Resistance Mutations.

Authors:  Kadie-Ann Williams; Pleuni Pennings
Journal:  G3 (Bethesda)       Date:  2020-04-09       Impact factor: 3.154

Review 5.  Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop.

Authors:  D D Richman; D Havlir
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro.

Authors:  S Hayashi; D W Norbeck; W Rosenbrook; R L Fine; M Matsukura; J J Plattner; S Broder; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 8.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

9.  Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.

Authors:  Alison F Feder; Kristin N Harper; Chanson J Brumme; Pleuni S Pennings
Journal:  Elife       Date:  2021-09-02       Impact factor: 8.140
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.